[1,4] MECHANISM OF ACTION Semaglutide is a GLP-1 receptor agonist [Figure 1] that enhances insulin secretion while reducing glucagon release
Annu Rev Immunol 32:609634
One clinical trial took a look at the extent of total body weight lost with consistent use of semaglutide over time and showed that at 68 weeks of consistent semaglutide use [2]: 69.1% of participants had lost more than 10% of their total body weight 50.5% of participants had lost more than 15% of their total body weight Overall, 1 in 3 participants lost at least 20% of their total body weight The average total body weight loss was 14.9% Most importantly, while clinical trials and studies show just how effective semaglutide is for losing weight, using this medication also helps improve health-related quality of life in many other ways [3]
While single-target drugs have reached the market faster in China due to earlier research, multi-target drugs are expected to have stronger long-term effects and greater market acceptance
Wegovy 7.2mg is not yet available on the NHS
Metabolism of GLP-1 and the therapeutic actions of long-lasting agonists GLP-1 has an extremely short half-life once released in the plasma, ranging from 211 minutes(Deacon et al., 1995
.png)
